This report was first published by Endpoints News. To see the original version, click here
A leader of the next wave of AI-driven biotechs completed one of the industry’s largest IPOs in years, although the milestone was tarnished by a rough first few hours of trading for the new stock.
Earlier Friday — minutes after ringing Nasdaq’s opening bell and surrounded by several dozen co-workers — Generate:Biomedicines CEO Mike Nally spoke with Endpoints News about the Somerville, MA-based biotech’s plans for using its raise of about $400 million.
您已阅读18%（544字），剩余82%（2561字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。